All In Biotech

Drug Trial Radar · NCT04788017

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Group, Single Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Feb 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Mar 24, 2021

Primary completion

Jun 14, 2021

Study completion Jul 22, 2021

Sponsor

Sponsor type
Industry
First posted
Mar 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Health services research
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ziresovir following a single ascending oral dose administration in healthy adult subjects under fasted conditions.

Conditions

  • Healthy Subjects

Interventions

  • ZiresovirDrug

    Planned treatments are: * Cohort 1: 300 mg of ziresovir * Cohort 2: up to 600 mg of ziresovir * Cohort 3: up to 900 mg of ziresovir

  • PlaceboOther

    Planned treatments are: * Cohort 1: 300 mg of placebo * Cohort 2: up to 600 mg of placebo * Cohort 3: up to 900 mg of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. numbers of all AEsTime frame: through study completion, an average of 22 days
  2. percentages of all AEsTime frame: through study completion, an average of 22 days
  3. change from baseline in systolic and diastolic blood pressureTime frame: screen/day -1/day 1/day 2/day 3/day4
  4. change from baseline in pulse rateTime frame: screen/day -1/day 1/day 2/day 3/day4
  5. change from baseline in respiratory rateTime frame: screen/day -1/day 1/day 2/day 3/day4
  6. change from baseline in oral temperatureTime frame: screen/day -1/day 1/day 2/day 3/day4
  7. change from baseline in Prothrombin time/International Normalized RatioTime frame: screen/day -1/day 2/day4
  8. change from baseline in Thrombin timeTime frame: screen/day -1/day 2/day4
  9. change from baseline in activated Partial Thromboplastin timeTime frame: screen/day -1/day 2/day4
  10. change from baseline in Hemoglobin (Hgb) countTime frame: screen/day -1/day 2/day4
  11. change from baseline in Hematocrit (Hct)Time frame: screen/day -1/day 2/day4
  12. change from baseline in Platelet countTime frame: screen/day -1/day 2/day4
  13. change from baseline in Red blood cell (RBC) countTime frame: screen/day -1/day 2/day4
  14. change from baseline in White blood cell (WBC) count with differentialTime frame: screen/day -1/day 2/day4
  15. change from baseline in Specific gravity from urinalysisTime frame: screen/day -1/day 2/day4
  16. change from baseline in pH from urinalysisTime frame: screen/day -1/day 2/day4
  17. change from baseline in Protein from urinalysisTime frame: screen/day -1/day 2/day4
  18. change from baseline in Glucose from urinalysisTime frame: screen/day -1/day 2/day4
  19. change from baseline in Ketones from urinalysisTime frame: screen/day -1/day 2/day4
  20. change from baseline in Bilirubin from urinalysisTime frame: screen/day -1/day 2/day4
  21. change from baseline in Blood from urinalysisTime frame: screen/day -1/day 2/day4
  22. change from baseline in Nitrites from urinalysisTime frame: screen/day -1/day 2/day4
  23. change from baseline in Leukocytes from urinalysisTime frame: screen/day -1/day 2/day4
  24. change from baseline in Urobilinogen from urinalysisTime frame: screen/day -1/day 2/day4
  25. Incidence of abnormal Microscopic urine analysisTime frame: screen/day -1/day 2/day4
  26. change from baseline in heart rate-corrected QT interval from resting 12-lead ECGsTime frame: screen/day -1/day1/day2/day4
  27. change from baseline in heart rate from resting 12-lead ECGsTime frame: screen/day -1/day1/day2/day4
  28. change from baseline in QRS intervals from resting 12-lead ECGsTime frame: screen/day -1/day1/day2/day4
  29. change from baseline in treatment-emergent T-wave morphology from resting 12-lead ECGsTime frame: screen/day -1/day1/day2/day4
  30. change from baseline in appearance of U-waves from resting 12-lead ECGsTime frame: screen/day -1/day1/day2/day4
  31. Incidence of abnormal physical findingsTime frame: screen/day -1/day2/day3/day4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Frontage

    Secaucus, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.